Mankind Pharma Q2 FY27 Revenue Up 17.3% to ₹4,338 Cr
Mankind Pharma announced its financial results for Q2 and H1 FY27, reporting a strong 17.3% year-on-year revenue growth to ₹4,338 Crore for the second quarter. EBITDA increased by 27.2% to ₹1,175 Crore, and PAT rose by 37.7% to ₹716 Crore. The domestic business showed robust growth of 14.8%, driven by key brands in cardiac, anti-diabetes, and gastro segments. International business also performed well, with a 32.7% increase in revenue. For the half-year ended September 30, 2026, revenue grew 15.1% to ₹8,368 Crore, with EBITDA up 26.7% and PAT up 24.7%. The company highlighted strategic entry into Next-Generation CAR-T therapies through the acquisition of Armed Cell Therapeutics, strengthening its R&D capabilities.
Key Highlights
- Q2 FY27 revenue surged 17.3% YoY to ₹4,338 Crore.
- EBITDA and PAT grew by 27.2% and 37.7% respectively.
- Domestic business delivered strong 14.8% revenue growth.
- International revenue saw a significant 32.7% increase.
- Acquisition of Armed Cell Therapeutics strengthens R&D.
Price Impact
More from MANKIND